OncoMatch/Clinical Trials/NCT06523699
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Is NCT06523699 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Recombinant glycosylated human interleukin-7 and Melphalan for multiple myeloma.
Treatment: Recombinant glycosylated human interleukin-7 · Melphalan — This is a two-arm, open-label, randomized, single-site, pilot study testing the addition of CYT107 following autologous hematopoietic cell transplant (AHCT) in patients with multiple myeloma (MM). The hypothesis of this study is that recombinant human CYT107 can be safely administered after AHCT and will promote quantitative and qualitative T cell reconstitution, which will be associated with enhanced tumor cell clearance and reduced infectious complications. Patients will be randomized to either the intervention arm that will receive CYT107 + standard of care melphalan and AHCT or to the control arm that will receive standard of care melphalan and AHCT only.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Adequate bone marrow function (details not specified)
Kidney function
Creatinine clearance ≥ 30 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 2 x IULN; AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
Adequate bone marrow and organ function as defined below: Total bilirubin ≤ 2 x IULN; AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN; Creatinine clearance ≥ 30 mL/min by Cockcroft-Gault
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify